PLoS ONE (Jan 2013)

Noninvasive identification of viable cell populations in docetaxel-treated breast tumors using ferritin-based magnetic resonance imaging.

  • YoonSeok Choi,
  • Hoe Suk Kim,
  • Kyoung-Won Cho,
  • Kyung-Min Lee,
  • Yoon Jung Yi,
  • Sung-Jong Eun,
  • Hyun Jin Kim,
  • Jisu Woo,
  • Seung Hong Choi,
  • Taeg-Keun Whangbo,
  • ChulSoo Choi,
  • Dong-Young Noh,
  • Woo Kyung Moon

DOI
https://doi.org/10.1371/journal.pone.0052931
Journal volume & issue
Vol. 8, no. 1
p. e52931

Abstract

Read online

BACKGROUND: Cancer stem cells (CSCs) are highly tumorigenic and are responsible for tumor progression and chemoresistance. Noninvasive imaging methods for the visualization of CSC populations within tumors in vivo will have a considerable impact on the development of new CSC-targeting therapeutics. METHODOLOGY/PRINCIPAL FINDINGS: In this study, human breast cancer stem cells (BCSCs) transduced with dual reporter genes (human ferritin heavy chain [FTH] and enhanced green fluorescence protein [EGFP]) were transplanted into NOD/SCID mice to allow noninvasive tracking of BCSC-derived populations. No changes in the properties of the BCSCs were observed due to ferritin overexpression. Magnetic resonance imaging (MRI) revealed significantly different signal intensities (R(2)* values) between BCSCs and FTH-BCSCs in vitro and in vivo. In addition, distinct populations of pixels with high R(2)* values were detected in docetaxel-treated FTH-BCSC tumors compared with control tumors, even before the tumor sizes changed. Histological analysis revealed that areas showing high R(2)* values in docetaxel-treated FTH-BCSC tumors by MRI contained EGFP+/FTH+ viable cell populations with high percentages of CD44+/CD24- cells. CONCLUSIONS/SIGNIFICANCE: These findings suggest that ferritin-based MRI, which provides high spatial resolution and tissue contrast, can be used as a reliable method to identify viable cell populations derived from BCSCs after chemotherapy and may serve as a new tool to monitor the efficacy of CSC-targeting therapies in vivo.